Terminated PHASE2 INTERVENTIONAL 2-arm NCT00369915

The Antidepressant Efficacy of the Anticholinergic Scopolamine

Sponsor: National Institute of Mental Health (NIMH)

Conditions Bipolar Depression Unipolar Depression

Interventions Scopolamine

Updated 6 times since 2017 Last updated: Sep 22, 2016 Started: Aug 31, 2006 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

Other terminated trials from National Institute of Mental Health (NIMH)

See all terminations from National Institute of Mental Health (NIMH)

Other Bipolar Depression trials with similar outcome

Browse all Bipolar Depression trials

This PHASE2 trial investigates Bipolar Depression and Unipolar Depression and is currently terminated or withdrawn. National Institute of Mental Health (NIMH) leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Mental Health (NIMH)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States